Galera Therapeutics, Inc.
Galera Therapeutics, Inc. (GRTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GRTX · as of Jun 30, 2022
Ownership Breakdown
40
Institutional Holders
▼ 10 vs Q1
$13.71M
Total Inst. Value
▼ $13.11M vs Q1
75.89M
Shares Outstanding
freeFloat 60.13%
10.55M
13F Shares Held
▼ 734,389 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GRTX largest shareholders · institutional ownership
Q2 2022 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 3.08M | 11.50% | 11.50% | $4.01B | Aug 15, 2022 | — held |
NOVO HOLDINGS A/S pharmaceutical preparations | 2.46M | 9.17% | 9.17% | $3.20B | Aug 15, 2022 | — held |
BLACKSTONE INC. pharmaceutical preparations | 1.68M | 6.26% | 6.26% | $2.18B | Aug 15, 2022 | — held |
TEKLA CAPITAL MANAGEMENT LLC pharmaceutical preparations | 898.4K | 3.35% | 3.35% | $1.17B | Jul 29, 2022 | — held |
NAN FUNG GROUP HOLDINGS LTD pharmaceutical preparations | 613.2K | 2.29% | 2.29% | $797.00M | Aug 12, 2022 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 436.0K | 1.63% | 1.63% | $567.00M | Aug 12, 2022 | ▼ 1.4K |
BLACKROCK INC. pharmaceutical preparations | 314.7K | 1.17% | 1.17% | $410.00M | Aug 12, 2022 | ▼ 6.6K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 242.4K | 90.36% | 90.36% | $315.00M | Aug 12, 2022 | ▼ 196.8K |
BRIDGEWAY CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 187.0K | 69.72% | 69.72% | $243.00M | Aug 15, 2022 | ▲ 40.0K |
ENSIGN PEAK ADVISORS, INC pharmaceutical preparations | 151.8K | 56.59% | 56.59% | $197.00M | Aug 12, 2022 | ▲ 112.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2022 vs prior quarter
Q2 2022
7
Increased
+229.6K shares2
New Positions
first time holders20
Decreased
−912.4K shares7
Sold Out
fully exitedNet shares change (top 50)
682.7K
+229.6K / −912.4K
Net new holders
-18
2 new / 7 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GRTX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Emerald Bioventures, LLC 10 percent owner | May 15, 2026 | C-Conversion | 20,813,818 | — | — | 61.03M | Form 4 ↗ |
Emerald Bioventures, LLC 10 percent owner | May 15, 2026 | C-Conversion | 20,813.819 | — | — | 0 | Form 4 ↗ |
FRIEDMAN MICHAEL R. director | Apr 7, 2026 | C-Conversion | 5,336,870 | — | — | 5.34M | Form 4 ↗ |
FRIEDMAN MICHAEL R. director | Apr 7, 2026 | C-Conversion | 5,336.87 | — | — | 3.0K | Form 4 ↗ |
CHANG NANCY T
| Apr 7, 2026 | C-Conversion | 1,180,611 | — | — | 8.83M | Form 4 ↗ |
CHANG NANCY T
| Apr 7, 2026 | C-Conversion | 1,180.611 | — | — | 661.309 | Form 4 ↗ |
Sorensen Mel President and CEO | Nov 20, 2025 | Sale | 70,000 | $0.02 | $1.4K | 195.0K | Form 4 ↗ |
Sussman Joel F. Chief Accounting Officer | May 1, 2025 | Award | 2,000,000 | $0.02 | $44.0K | 2.00M | Form 4 ↗ |
Sorensen Mel President and CEO | May 1, 2025 | Award | 6,000,000 | $0.02 | $132.0K | 6.00M | Form 4 ↗ |
LOKAY KEVIN G director | Feb 24, 2025 | Award | 48,000 | $0.04 | $2.0K | 48.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Galera Therapeutics, Inc. (GRTX) is primarily owned by institutional investors, who hold approximately 13.9% of total shares outstanding. Company insiders own approximately 39.87%, while retail and public investors account for the remaining 46.23%.
The largest institutional shareholder of Galera Therapeutics, Inc. is SOFINNOVA INVESTMENTS, INC., holding approximately 3.08 million shares — equal to 11.50% of outstanding shares — as of June 30, 2022.
A total of 40 institutional investors currently hold GRTX stock, with a combined institutional value of approximately $13,713,730 as of the most recent 13F filing period.
Frequently asked questions
GRTX ownershipGalera Therapeutics, Inc. (GRTX) is primarily owned by institutional investors, who hold approximately 13.9% of shares. The largest shareholder is SOFINNOVA INVESTMENTS, INC. with a 11.50% stake. Company insiders hold 39.87%. Data sourced from SEC Form 13F as of June 30, 2022.